Blue Cross NC policies

Search Blue Cross NC's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

Checking prior authorization for 81479? Open Blue Cross NC’s official lists and confirm the member’s product there.

101 policies name 81479, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Blue Cross NC policies
PolicyDetailsCodesSource
Genetic and Molecular TestingCommercial1Original policy ↗
Genetic Testing for Lipoprotein A Variant(s) as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment AHS – M2082M2082 · Commercial1Original policy ↗
Genetic Testing for Lipoprotein A Variant(s) as a Decision Aid for Aspirin Treatment and/or CVD Risk Assessment AHS – M2082M2082 · Commercial1Original policy ↗
Genetic Testing for Lactase Insufficiency AHS – M2080M2080 · Commercial2Original policy ↗
Fibromyalgia Testing AHS - M2177M2177 · Commercial3Original policy ↗
Gene Expression Based Assays for Cancers of Unknown Primary AHS - M2065M2065 · Commercial4Original policy ↗
Genetic and Molecular TestingEffective Feb 1, 2026 · Commercial4Original policy ↗
Genetic and Molecular TestingCommercial4Original policy ↗
Genetic Expression Profiling and Genetic Testing for Familial Cutaneous Malignant Melanoma AHS – M2037M2037 · Commercial4Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial4Original policy ↗
Genetic Testing for Li-Fraumeni Syndrome AHS – M2081M2081 · Commercial4Original policy ↗
Molecular Profiling for Cancers of Unknown Primary Origin AHS- M2065AHS-M2065 · Commercial4Original policy ↗
Serum Testing for Evidence of Mild Traumatic Brain Injury AHS - G2151G2151 · Commercial4Original policy ↗
Genetic Testing for CHARGE Syndrome AHS - M2070M2070 · Commercial5Original policy ↗
Genetic Testing for Familial Hypercholesterolemia AHS – M2137M2137 · Commercial5Original policy ↗
Genetic Testing for Fanconi Anemia AHS – M2077M2077 · Commercial5Original policy ↗
Genetic Testing for Hereditary Hemochromatosis AHS – M2012M2012 · Commercial5Original policy ↗
Genetic Testing for Macular Degeneration AHS-M2083AHS-M2083 · Commercial5Original policy ↗
Molecular Testing for Pulmonary Disease AHS - M2160M2160 · Commercial5Original policy ↗
Mutation Testing for Limb-Girdle Muscular Dystrophies AHS – M2128M2128 · Commercial5Original policy ↗
Genetic Testing and Genetic Expression Profiling in Patients with Uveal Melanoma AHS - M2071M2071 · Commercial6Original policy ↗
Genetic Testing for Familial Hypercholesterolemia AHS – M2137M2137 · Commercial6Original policy ↗
Molecular Markers in Fine Needle Aspirates of the Thyroid AHS - M2108M2108 · Commercial6Original policy ↗
Multigene Expression Assay for Predicting Colon Cancer Recurrence AHS-M2111AHS-M2111 · Commercial6Original policy ↗
Testing for Alpha-1 Antitrypsin Deficiency AHS - M2068M2068 · Commercial6Original policy ↗
Testing for Alpha-1 Antitrypsin Deficiency AHS - M2068M2068 · Commercial6Original policy ↗
Genetic Testing for Connective Tissue Disorders AHS - M2144M2144 · Commercial7Original policy ↗
Genetic Testing for Cystic Fibrosis AHS – M2017M2017 · Commercial7Original policy ↗
Genetic Testing for Hereditary Pancreatitis AHS – M2079M2079 · Commercial7Original policy ↗
Genetic Testing for Hereditary Pancreatitis AHS – M2079M2079 · Commercial7Original policy ↗
Laboratory Procedures Reimbursement Policy AHS - R2162R2162 · Commercial7Original policy ↗
Molecular Panel Testing of Cancers to Identify Targeted Therapy AHS - M2109M2109 · Commercial8Original policy ↗
Genetic Testing for Polyposis Syndromes AHS-M2024AHS-M2024 · Commercial9Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial10Original policy ↗
Genetic Testing for Epilepsy AHS – M2075M2075 · Commercial10Original policy ↗
Genetic Testing for Epilepsy AHS – M2075 NotificationM2075 · Commercial10Original policy ↗
Molecular Analysis for Gliomas AHS - M2139M2139 · Commercial10Original policy ↗
Pancreatic Cancer Risk Testing Using Pancreatic Cyst Fluid AHS - M2114M2114 · Commercial10Original policy ↗
Chromosomal Microarray and Low-pass Whole Genome Sequencing AHS - M2033M2033 · Commercial11Original policy ↗
Genetic Testing for Fanconi Anemia AHS – M2077M2077 · Commercial11Original policy ↗
Genetic Testing for Hereditary Hearing Loss AHS – G2148G2148 · Commercial11Original policy ↗
Genetic Testing for Ophthalmologic Conditions AHS-M2083AHS-M2083 · Commercial13Original policy ↗
Molecular Analysis for Gliomas AHS - M2139M2139 · Commercial13Original policy ↗
Testing for Colorectal Cancer Management AHS - M2026M2026 · Commercial13Original policy ↗
Testing of Homocysteine Metabolism Related Conditions AHS - M2141M2141 · Commercial13Original policy ↗
Testing of Homocysteine Metabolism Related Conditions AHS - M2141 NotificationM2141 · Commercial13Original policy ↗
Venous Thrombosis Risk Testing AHS – M2041M2041 · Commercial13Original policy ↗
Genetic Markers for Assessing Risk of Cardiovascular Disease AHS - M2180M2180 · Commercial14Original policy ↗
Genetic Testing for Cardiac Ion Channelopathies AHS – 2025Commercial14Original policy ↗
Venous and Arterial Thrombosis Risk Testing AHS - M2041M2041 · Commercial14Original policy ↗

Back to Blue Cross NC · Blue Cross NC prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.